[[{"type":"media","view_mode":"media_large","fid":"26","attributes":{"alt":"","class":"media-image","id":"1","typeof":"foaf:Image"}}]]
Personalised medications for Heart failure patients
- Despite life saving therapies, mortality & rehospitalisation's remains high.
- Not all patients benefit from the same drug.
- Response to treatment is not homogenous.
Identifying patients with a poor outcome on currently recommended therapy may lead to further development of targeted therapies, eventually leading to improvements in outcome for patients with heart failure in the UK
“This is in part because not everyone responds to treatments in the same way. While some patients may respond very well to tablets for heart failure, others may have no benefit at all and may even experience harmful side effects. In other words, there is a need for treatment to be ‘tailored’ to the individual patient” Prof Lang.
BIOSTAT TAYSIDE-CHF is the very first attempt to provide a model that predicts response to therapy, incorporating demographics, biomarkers, genomic and proteomic analysis.
By linking diagnostic and biomarker research throughout all stages of drug research and development; we can
- Help to better understand the complexity of diseases.
- Improve quality and efficiency of results in Research & Development.
- Provide better, safer and more efficient treatments.